PI3K-AKT信号通路qBiomarker体细胞突变PCR芯片 PI3K-AKT Signaling Pathway qBiomarker Mutation PCR Array

“英拜为您实验加速”
技术服务网址：http://www.yingbio.com/
服务热线：400-696-6643、 18019265738
邮箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

PI3K-AKT Signaling Pathway qBiomarker Mutation

PCR Array 

PI3K-AKT信号通路qBiomarker体细胞突变PCR芯片
 

Product	Species	Technology	Cat. No.
PI3K-AKT Signaling Pathway qBiomarker Mutation PCR Array	Human	Somatic Mutation	SMH-014A

The Human PI3K-AKT Signaling Pathway qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid and accurate profiling of the somatic mutation status for key genes in the PI3K-PTEN pathway: AKT1, AKT3, PIK3CA, PIK3R1, PIK3R5, PTEN, and STK11/LKB1. Components in this pathway are frequently mutated in human cancers (mutated in >30% solid tumor types) and therefore warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. The utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions has been demonstrated in numerous research studies. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human PI3K-AKT Signaling Pathway qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of the PI3K-Akt pathway and provides the potential to discover and verify drug target biomarkers for a variety of human cancers involving the PI3K-Akt signaling pathway and downstream effectors. This array includes 87 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in the PI3K-AKT pathway. These mutations were chosen from curated, comprehensive, somatic mutation databases and peer-reviewed scientific literature. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments.
The qBiomarker Somatic Mutation PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.
PI3K-AKT信号通路qBiomarker体细胞突变PCR芯片是一个翻译研究工具,用于快速,准确,全面剖析PI3K-PTEN中体细胞突变的关键基因: AKT1, AKT3, PIK3CA, PIK3R1, PIK3R5, PTEN和STK11/LKB1. 这些突变保证广泛的研究,以提高致癌作用的理解和鉴定潜在的药物靶点。已有许多研究通过单个和多个体细胞突变状态信息鉴定关键信号转导中断。例如,EGFR和KRAS基因的突变状态可以预测某些药物针对这些分子的生理反应。PI3K-AKT信号通路qBiomarker体细胞突变PCR芯片以其全面的内容覆盖范围，用于研究PI3K-AKT的环境突变且有潜力用于发现靶向药物的生物标记和多种人类癌症的生物标记包括PI3K-AKT信号通路和下游效应器。这个芯片包含83个DNA突变序列用于检测最频繁的，功能性验证，PI3K-AKT通路和生物学重要的突变。这些突变的选择根据全面的体细胞突变数据库和文献。简单的产品模式和操作程序让任何一个具备实时定量PCR仪的实验室都可进行常规的体细胞突变分析。
AKT genes:
The mutation assays detects the best known AKT mutation, c.49G>A, p.E17K (AKT1; a PH domain mutation that results in constitutive targeting of AKT1 to plasma membrane), the activating mutations c.145G>A, p.E49K (AKT1) and c.511G>A, p.G171R (AKT3).
PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) gene:
The mutation assays covered on this panel can detect 37 most frequently occurring PIK3CA mutations that are mainly clustered in the kinase domain (activating mutations) and in the P539-E545 region and vicinity, which are helical domain mutations that mimic activation by growth factors. The assays allow a comprehensive profiling of PIK3CA mutations that have been identified in a variety of cancers.
PIK3R1 and PIK3R5 (PI3K regulatory subunit) genes:
Two recurrent disinhibitory (c.1126G>A, p.G376R and c.1690A>G, p.N564D) mutations in PIK3R1 and a recurrent oncogenic mutation in PIK3R5 are included.
PTEN gene:
Included on the panel are 33 most commonly detected PTEN loss-of-function mutations that are mainly due to truncation or point mutation-caused phosphatase inactivation.
STK11/LKB1 gene:
Included on the panel are 11 most commonly detected STK11/LKB1 inactivation mutations that are mainly due to truncation or point mutation.

工作原理：

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

 

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS®